Lupin's Q3 FY26: A Quarter of Record Revenues and Strategic Momentum

Lupin Limited, a global pharmaceutical leader, has once again demonstrated robust performance, reporting its 14th consecutive quarter of year-on-year growth. The company's Q3 FY26 results reveal record revenues and significant strides in strategic initiatives, reinforcing its position in key global markets. Net Sales for the quarter stood at INR 7,100.5 crore, marking a substantial 26.4% year-on-year increase. This impressive top-line growth translated into a strong EBITDA of INR 2,209.5 crore, up 61.8% YoY, with EBITDA margins expanding by 681 basis points to 31.1%. Net Income for the quarter was INR 1,175.6 crore, reflecting a 37.5% YoY growth, despite a one-time exceptional item of INR 426.6 crore.

The growth was broad-based, with most regions, including India, Europe, LATAM, and other emerging markets, delivering double-digit year-on-year growth. The US business recorded its highest-ever sales, driven by new product launches and a strong base business. India's core prescription business also grew significantly, outpacing the Indian Pharma Market (IPM).

Segmental Performance and Growth Drivers

Lupin's performance across its key segments highlights strategic execution and market penetration. The United States market emerged as a powerhouse, contributing 44% of the total revenue with INR 3,113.2 crore. This growth was propelled by new product introductions such as Tolvaptan, where Lupin benefited from generic exclusivity, and the successful launch of gRisperdal Consta® with CGT exclusivity, a product from its proprietary Nanomi long-acting injectable platform. The company also secured US FDA approval for Armlupeg™ (pegfilgrastim-unne), its first biosimilar for the US market, with a launch expected before the end of the quarter, signaling significant future potential in the institutional business.

India, the domestic market, accounted for 29% of the revenue at INR 2,038.7 crore. The core prescription business grew by 10.9% year-on-year, aligning with the IPM growth. The chronic segment's share increased to 67% of the portfolio, up from 65% in the previous quarter, demonstrating a successful shift in focus. Key therapeutic areas like Respiratory and Cardiovascular grew faster than the market. Other Developed Markets (comprising Canada, Australia, and Europe) contributed 11% of sales, while Emerging Markets, led by Brazil, Mexico, and the Philippines, showed an impressive 42% year-on-year growth, contributing 13% to the total revenue. The API segment also grew by 24% YoY, reaching INR 219.5 crore.

Strategic Initiatives and Future Outlook

Lupin's strategic roadmap is clearly focused on innovation, market expansion, and operational excellence. The company is pivoting its R&D towards complex generics and biosimilars, aiming to become a CGx powerhouse with 20 complex product launches and three biosimilar filings by 2028. This includes a robust pipeline of 45+ injectables and 20+ inhalations, with a target of over 100 new product launches and 65%+ revenue share from complex products by FY31.

In a significant move, Lupin announced a strategic collaboration with TB Alliance to advance Telacebec for tuberculosis treatment, showcasing its commitment to addressing unmet medical needs. The company also partnered with Galenicum Health for injectable Semaglutide in 23 countries, further bolstering its diabetes and obesity portfolio. This aligns with the launch of new divisions in India, including one dedicated to obesity, ahead of the Semaglutide launch.

Management expects full-year EBITDA margins to be in the range of 27-28%, an upward revision from earlier guidance. R&D expenditure is projected at 7.5-8.5% of sales, reflecting continued investment in its complex portfolio. The company's net cash position has significantly improved to INR 2,879 crore, providing ample financial flexibility for future strategic investments, including potential acquisitions in specialty assets.

Sustainability and Operational Excellence

Lupin's commitment to sustainability is evident in its top-tier ESG ratings. The company achieved the highest 'A' leadership rating from CDP for Climate Change and Water Security, a significant improvement from previous years. This recognition places Lupin among global leaders in corporate transparency and environmental action. Furthermore, its greenhouse gas emissions reduction goals have been formally approved by the Science Based Targets initiative (SBTi), underscoring its dedication to a sustainable future. Lupin also boasts an S&P Global ESG score of 91 out of 100, cementing its sustainability leadership in the global pharma industry.

Operationally, Lupin continues to enhance its manufacturing and quality standards. The company reported successful FDA inspections for its Pune Biotech, Nagpur Unit-II, and Aurangabad facilities, with zero observations for Nagpur Unit-I. These achievements underscore Lupin's unwavering commitment to maintaining the highest global quality and regulatory standards across all its sites.

Lupin's Q3 FY26 performance underscores a company in strong momentum, strategically investing in its future while delivering robust financial results. With a clear focus on complex products, market expansion, and sustainability, Lupin is well-positioned for sustained long-term growth and continued value creation for its stakeholders.